The changes at the top take effect July 1. Both Hudson and Strigini will report to Novartis Chief Executive Joe Jimenez. And as part of the overhaul, David Epstein, who headed the Novartis oncology business for six years, is leaving the company. One Wall Street analyst is not surprised by the reorganization.